The FDA has approved a new drug called Vabrinty (leuprolide acetate) for the treatment of advanced prostate cancer. Vabrinty is a hormone therapy that lowers certain hormones that can help cancer grow. It is given as a shot under the skin by a healthcare provider. Depending on the dose, shots can be given every 1, 3, 4, or 6 months. This flexibility allows doctors to choose a schedule that works best for each patient.
Vabrinty is for men with advanced prostate cancer. The approval is based on studies showing it works well to control the cancer. The most common side effects include hot flashes, tiredness, and injection site reactions. Like other similar drugs, Vabrinty may cause a temporary increase in certain symptoms at the start of treatment.
This approval means there is another option for treating advanced prostate cancer. It does not mean that Vabrinty is right for everyone. Patients should talk to their doctor about whether this drug is a good choice for their specific situation. The doctor can explain the benefits and risks and help decide on the best treatment plan.